Changes

HAEM5:Follicular dendritic cell sarcoma (view source)

Revision as of 11:36, 1 September 2024

2,068 bytes added , 11:36, 1 September 2024

no edit summary

Line 1: Line 1:

−

[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]

+

[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 7: Line 7:

}}</blockquote>

−

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author_Instructions]] and [[Frequently Asked Questions (FAQs)|FAQs]] as well as contact your [[Leadership|Associate Editor]] or [mailto:CCGA@cancergenomics.org Technical Support])

+

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click nearby within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author_Instructions]] and [[Frequently Asked Questions (FAQs)|FAQs]] as well as contact your [[Leadership|Associate Editor]] or [mailto:CCGA@cancergenomics.org Technical Support])

==Primary Author(s)*==

Line 41: Line 41:

==Clinical Features==

−

Put your text here and fill in the table (''Instruction: Can include references in the table'')

+

Put your text here and fill in the table (''Instruction: Can include references in the table. Do not delete table.'')

{| class="wikitable"

|'''Signs and Symptoms'''

−

|EXAMPLE Asymptomatic (incidental finding on complete blood counts)

+

|EXAMPLE: Asymptomatic (incidental finding on complete blood counts)

−

EXAMPLE B-symptoms (weight loss, fever, night sweats)

+

EXAMPLE: B-symptoms (weight loss, fever, night sweats)

−

EXAMPLE Fatigue

+

EXAMPLE: Fatigue

−

EXAMPLE Lymphadenopathy (uncommon)

+

EXAMPLE: Lymphadenopathy (uncommon)

|-

|'''Laboratory Findings'''

−

|EXAMPLE Cytopenias

+

|EXAMPLE: Cytopenias

−

EXAMPLE Lymphocytosis (low level)

+

EXAMPLE: Lymphocytosis (low level)

|}

Line 100: Line 100:

!Notes

|-

−

|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)

+

|EXAMPLE: t(9;22)(q34;q11.2)||EXAMPLE: 3'ABL1 / 5'BCR||EXAMPLE: der(22)||EXAMPLE: 20% (COSMIC)

−

EXAMPLE 30% (add reference)

+

EXAMPLE: 30% (add reference)

|Yes

|No

|Yes

−

|EXAMPLE

+

|EXAMPLE:

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).

Line 111: Line 111:

−

<blockquote class='blockedit'>{{Box-round|title=~~v4:Chromosomal Rearrangements (Gene Fusions)~~|~~The content below was from the old template. Please incorporate above.~~}}

+

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification}}

The following rearrangements have been reported in individual cases, but whether they are recurrent is not yet known.

Line 119: Line 119:

!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence

|-

−

|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 5%

+

|EXAMPLE: t(9;22)(q34;q11.2)||EXAMPLE: 3'ABL1 / 5'BCR||EXAMPLE: der(22)||EXAMPLE: 5%

|-

−

|EXAMPLE t(8;21)(q22;q22)||EXAMPLE 5'RUNX1 / 3'RUNXT1||EXAMPLE der(8)||EXAMPLE 5%

+

|EXAMPLE: t(8;21)(q22;q22)||EXAMPLE: 5'RUNX1 / 3'RUNXT1||EXAMPLE: der(8)||EXAMPLE: 5%

|}

Line 127: Line 127:

==Individual Region Genomic Gain / Loss / LOH==

−

Put your text here and fill in the table (''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'')

+

Put your text here and fill in the table (''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.'')

{| class="wikitable sortable"

Line 137: Line 137:

!Notes

|-

−

|EXAMPLE

+

|EXAMPLE:

7

−

|EXAMPLE Loss

+

|EXAMPLE: Loss

−

|EXAMPLE

+

|EXAMPLE:

chr7:1- 159,335,973 [hg38]

−

|EXAMPLE

+

|EXAMPLE:

chr7

Line 150: Line 150:

|Yes

|No

−

|EXAMPLE

+

|EXAMPLE:

Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).

|-

−

|EXAMPLE

+

|EXAMPLE:

8

−

|EXAMPLE Gain

+

|EXAMPLE: Gain

−

|EXAMPLE

+

|EXAMPLE:

chr8:1-145,138,636 [hg38]

−

|EXAMPLE

+

|EXAMPLE:

chr8

Line 167: Line 167:

|No

−

|EXAMPLE

+

|EXAMPLE:

Common recurrent secondary finding for t(8;21) (add reference).

Line 173: Line 173:

==Characteristic Chromosomal Patterns==

−

Put your text here (''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')

+

Put your text here (''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.'')

{| class="wikitable sortable"

Line 183: Line 183:

!Notes

|-

−

|EXAMPLE

+

|EXAMPLE:

Co-deletion of 1p and 18q

Line 189: Line 189:

|No

−

|EXAMPLE:

+

|EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

|}

−

<blockquote class='blockedit'>{{Box-round|title=~~v4:Characteristic Chromosomal Aberrations / Patterns~~|~~The content below was from the old template. Please incorporate above.~~}}

+

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification}}

Although no recurrent chromosomal alterations have been identified in FDCS, the tumors often show complex karyotypes with loss of whole or partial chromosomes being the most frequent aberration. Losses frequently occur in regions harboring important tumor suppressor genes.<ref name=":2" />

Line 201: Line 201:

==Gene Mutations (SNV / INDEL)==

−

Put your text here and fill in the table (''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'')

+

Put your text here and fill in the table (''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well as either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable. Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Do not delete table.'')

{| class="wikitable sortable"

Line 211: Line 211:

!Notes

|-

−

|EXAMPLE: TP53; Variable LOF mutations

+

|EXAMPLE: TP53; Variable LOF mutations

−

EXAMPLE:

+

EXAMPLE:

EGFR; Exon 20 mutations

−

EXAMPLE: BRAF; Activating mutations

+

EXAMPLE: BRAF; Activating mutations

−

|EXAMPLE: TSG

+

|EXAMPLE: TSG

−

|EXAMPLE: 20% (COSMIC)

+

|EXAMPLE: 20% (COSMIC)

−

EXAMPLE: 30% (add Reference)

+

EXAMPLE: 30% (add Reference)

−

|EXAMPLE: IDH1 R123H

+

|EXAMPLE: IDH1 R123H

−

|EXAMPLE: EGFR amplification

+

|EXAMPLE: EGFR amplification

|

−

|EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference).

+

|EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference).

|}

Line 233: Line 233: −

<blockquote class='blockedit'>{{Box-round|title=~~v4:Gene Mutations (SNV/INDEL)~~|~~The content below was from the old template. Please incorporate above.~~}}

+

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification}}

Put your text here and/or fill in the tables

Line 351: Line 351:

!Type!!Gene/Region/Other

|-

−

|Concomitant Mutations||EXAMPLE IDH1 R123H

+

|Concomitant Mutations||EXAMPLE: IDH1 R123H

|-

−

|Secondary Mutations||EXAMPLE Trisomy 7

+

|Secondary Mutations||EXAMPLE: Trisomy 7

|-

−

|Mutually Exclusive||EXAMPLE EGFR Amplification

+

|Mutually Exclusive||EXAMPLE: EGFR Amplification

|}

Line 365: Line 365:

==Genes and Main Pathways Involved==

−

Put your text here and fill in the table (''Instructions: Can include references in the table.'')

+

Put your text here and fill in the table (''Instructions: Can include references in the table. Do not delete table.'')

{| class="wikitable sortable"

|-

!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome

|-

−

|EXAMPLE: BRAF and MAP2K1; Activating mutations

+

|EXAMPLE: BRAF and MAP2K1; Activating mutations

−

|EXAMPLE: MAPK signaling

+

|EXAMPLE: MAPK signaling

−

|EXAMPLE: Increased cell growth and proliferation

+

|EXAMPLE: Increased cell growth and proliferation

|-

−

|EXAMPLE: CDKN2A; Inactivating mutations

+

|EXAMPLE: CDKN2A; Inactivating mutations

−

|EXAMPLE: Cell cycle regulation

+

|EXAMPLE: Cell cycle regulation

−

|EXAMPLE: Unregulated cell division

+

|EXAMPLE: Unregulated cell division

|-

−

|EXAMPLE: KMT2C and ARID1A; Inactivating mutations

+

|EXAMPLE: KMT2C and ARID1A; Inactivating mutations

−

|EXAMPLE: Histone modification, chromatin remodeling

+

|EXAMPLE: Histone modification, chromatin remodeling

−

|EXAMPLE: Abnormal gene expression program

+

|EXAMPLE: Abnormal gene expression program

|}

−

<blockquote class='blockedit'>{{Box-round|title=~~v4:Genes and Main Pathways Involved~~|~~The content below was from the old template. Please incorporate above.~~}}

+

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification}}

FDCS primarily shows alterations in the NF-κB signaling pathway. Unlike the dendritic cell and histiocytic neoplasms of hematopoietic origin, aberrations in the MAPK pathway are uncommon.

Bailey.Glen

Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors

3,456

edits